DMS 0947 Exploratory Study of the Modulation of the Immune System by Vascular Endothelial Growth Factor (VEGF) Blockade in Patients With Glioblastoma Multiforme (GBM)

Trial Profile

DMS 0947 Exploratory Study of the Modulation of the Immune System by Vascular Endothelial Growth Factor (VEGF) Blockade in Patients With Glioblastoma Multiforme (GBM)

Completed
Phase of Trial: Phase 0

Latest Information Update: 30 May 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 24 May 2018 Status changed from active, no longer recruiting to completed.
    • 18 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
    • 02 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 Jul 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top